Literature DB >> 12692073

Which 5-ASA?

J C Mansfield.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12692073      PMCID： PMC1773654          DOI： 10.1136/gut.52.5.771

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  9 in total

Review 1.  Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.

Authors:  L Sutherland; D Roth; P Beck; G May; K Makiyama
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.

Authors:  J R B Green; J C Mansfield; J A Gibson; G D Kerr; P C Thornton
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

3.  A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.

Authors:  J C Mansfield; M H Giaffer; P A Cann; D McKenna; P C Thornton; C D Holdsworth
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

4.  Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

Authors:  F N Hussain; R A Ajjan; S A Riley
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

5.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.

Authors:  W Kruis; S Schreiber; D Theuer; J W Brandes; E Schütz; S Howaldt; B Krakamp; J Hämling; H Mönnikes; I Koop; M Stolte; D Pallant; U Ewald
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

6.  Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.

Authors:  J R Green; A J Lobo; C D Holdsworth; R J Leicester; J A Gibson; G D Kerr; H J Hodgson; K J Parkins; M D Taylor
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

7.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

Authors:  S Hanauer; J Schwartz; M Robinson; W Roufail; S Arora; J Cello; M Safdi
Journal:  Am J Gastroenterol       Date:  1993-08       Impact factor: 10.864

8.  A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.

Authors:  Douglas S Levine; Dennis S Riff; Ronald Pruitt; Lawrence Wruble; George Koval; David Sales; John K Bell; Lorin K Johnson
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

9.  Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.

Authors:  Ronald Pruitt; John Hanson; Michael Safdi; Lawrence Wruble; Robert Hardi; John Johanson; George Koval; Dennis Riff; Barry Winston; Amanda Cross; Pamela Doty; Lorin K Johnson
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.